Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA

American Kratom Association accuses FDA of using “inaccurate, extrapolated and distorted” information on adverse events and deaths allegedly associated with the use of kratom to justify scheduling it as a controlled substance. After FDA Commissioner Gottlieb says the criticism is unfounded and kratom has no future as a dietary ingredient in the US, the group asks for joint meeting with NIDA to discuss "public health policy that allows for consumers to safely use natural kratom."